Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study

被引:4
|
作者
Debourdeau, P. [1 ]
Arvers, P. [2 ]
Hij, A. [3 ,4 ,5 ]
Bennani, H. [6 ]
Desauw, C. [7 ]
Falvo, N. [8 ]
Ghiringhelli, F. [9 ]
Hamade, A. [10 ]
Vedrine, L. [11 ]
Farge, D. [3 ,4 ,5 ]
机构
[1] Inst St Catherine, Unite Soins Support, 250 Chemin Baigne Pieds CS 80005, F-84918 Avignon, France
[2] Univ Grenoble Alpes, Lab Interuniv Psychol, BP 47, F-38040 Grenoble 9, France
[3] Hop St Louis, AP HP, Unite Med Interne Malad Autoimmunes & Pathol Vasc, 1 Ave Claude Vellefawc, F-75010 Paris, France
[4] Univ Paris 07, Paris, France
[5] Grp Francophone Thrombose & Canc, Paris, France
[6] Hop Rene Huguenin, Inst Curie, 35 Rue Daily, F-92210 St Cloud, France
[7] Hop Claude Huriez, Serv Oncol, Rue Michel Polonowski, F-59037 Lille, France
[8] Hop Bocage, Serv Med Interne, 2 Blvd Marechal Lattre Tassigny, F-21000 Dijon, France
[9] Ctr Anti Cancereux Ctr GF Leclerc, 1 Rue Prof Mar, F-21000 Dijon, France
[10] Hop Emile Muller, Unite Pathol Vasc, 20 Rue Docteur Laennec, F-68070 Mulhouse 10, France
[11] Hop Amer Paris, Serv Doncol, 63 Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
关键词
LMWH; Acceptability; Cancer; Experience; Quality of life; Venous thromboembolism; VENOUS THROMBOEMBOLISM PROPHYLAXIS; CLINICAL-PRACTICE GUIDELINES; ANTICOAGULATION THERAPY; ATRIAL-FIBRILLATION; PALLIATIVE CARE; GUIDANCE; PREVENTION; ADHERENCE;
D O I
10.1007/s00520-019-04815-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Our objective was to compare patient's expectations to their experience and to identify factors predictive of patient's perception of long-term LMWH for the treatment of cancer-associated thrombosis (CAT). Methods Results from the validated Perception Anticoagulant Treatment Questionnaires (PACTQ) completed before inclusion (PACTQ1 for expectations) and at the end (PACTQ2 for convenience and satisfaction) of the 6-month TROPIQUE study were studied with principal component analysis. Possible predictive factors of improved perception of LMWH treatment were analyzed with the Kruskall-Wallis test. Results Among 409 included patients treated with LMWH, 269 PACT-Q1 and 139 PACT-Q2 were evaluable for treatment perception. Patients had high expectations (A1-A7 score of 26.7 +/- 3.5, max = 35). Treatment cost (A7 = 1.90 +/- 1.31) and concern about a mistake in anticoagulation (A5 = 1.93 +/- 1.12) had little importance while LMWH treatment was considered easy to use (A4 = 4.20 +/- 0.93). Six-month treatment with LMWH was associated with a high rate of convenience (B1-B11, C1-C2 = 55.1 +/- 8.38, max = 65) and a high satisfaction score (D1-D7 = 25.1 +/- 4.32, max = 35). Patients' confidence in treatment and perception of possible LMWH side effects were moderate while perception of autonomy and independence significantly improved at the end of the study compared to inclusion. PACT-Q2 satisfaction score was low in patients who experienced bleeding (PACT-Q2 24.1 +/- 3.3 vs. 25.1 +/- 4.3). LMWH twice daily tended to be found less convenient compared than once daily (53.3 +/- 7.2 vs. 55.0 +/- 8.3). Conclusion CAT patients had a good perception of the 6-month LMWH treatment when comparing expectations and experience. Using a quantitative scale validated in the general population for VTE and subcutaneous injection and including a large number of patients, bleeding complications and LMWH twice daily were associated with a nonsignificant trend towards a worsen perception.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 50 条
  • [31] Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
    Caroti, Kimberly Snow
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y. Y.
    Ekbom, Anders
    Carrier, Marc
    Cohen, Alexander T.
    Brescia, Christopher
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Schaefer, Bernhard
    Brobert, Gunnar
    Coleman, Craig I.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
  • [32] Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis
    Baloch, Maryam F.
    Adepoju, Adedimeji, V
    Falki, Vaibhavkumar
    Hajjaj, Mohsin
    Habet, Tatiana
    Habet, Karina
    Mahrosh, Amtul
    Kundu, Sumana
    Kataria, Janvi
    Mathew, Midhun
    Saka, Tugba
    Al-Tawil, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [33] Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
    Hull, Russell D.
    Pineo, Graham F.
    Brant, Rollin F.
    Mah, Andrew F.
    Burke, Natasha
    Dear, Richard
    Wong, Turnly
    Cook, Roy
    Solymoss, Susan
    Poon, Man-Chiu
    Raskob, Gary
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 (12): : 1062 - 1072
  • [34] Long-term treatment of deep venous thrombosis with a low molecular weight heparin (Tinzaparin): A prospective randomized trial
    Daskalopoulos, ME
    Daskalopoulou, SS
    Tzortzis, E
    Sfiridis, P
    Nikolaou, A
    Dimitroulis, D
    Kakissis, I
    Liapis, CD
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2005, 29 (06) : 638 - 650
  • [35] Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study
    Mah, Isabelle
    Gusto, Gaelle
    Quignot, Nadia
    Khachatryan, Artak
    Chaves, Jose
    Moniot, Audrey
    Andre, Lucas
    Van Roy, Sylvain
    Mokgokong, Ruth
    Bertoletti, Laurent
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [36] Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats
    O'Connell, Casey
    Escalante, Carmen P.
    Goldhaber, Samuel Z.
    McBane, Robert
    Connors, Jean M.
    Raskob, Gary E.
    ONCOLOGIST, 2021, 26 (01): : E8 - E16
  • [37] Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
    Akl, Elie A.
    Barba, Maddalena
    Rohilla, Sandeep
    Terrenato, Irene
    Sperati, Francesca
    Muti, Paola
    Schuenemann, Holger J.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2008, 27 (1)
  • [38] Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
    Elie A Akl
    Maddalena Barba
    Sandeep Rohilla
    Irene Terrenato
    Francesca Sperati
    Paola Muti
    Holger J Schünemann
    Journal of Experimental & Clinical Cancer Research, 27
  • [39] Long-term treatment with low-molecular-weight heparin prolonged the survival time for acute pulmonary embolism patients concurrent with malignancy: An observational analysis from a long-term follow-up study
    Zhang, Shuai
    Zhai, Zhenguo
    Yang, Yuanhua
    Zhu, Jianguo
    Gong, Juanni
    Xie, Wanmu
    Kuang, Tuguang
    Wang, Chen
    THROMBOSIS RESEARCH, 2015, 135 (04) : 582 - 587
  • [40] Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients
    Solier Lopez, Aurora
    Morillo Guerrero, Raquel
    Elias Hernandez, Teresa
    Jara Palomares, Luis
    Otero Candelera, Remedios
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46